Today's Undercover Winner | Market Checkup - 2/27/14 | The Motley Fool | Summary and Q&A

TL;DR

Anaka and Miland Pharmaceuticals were the winners of the week, while Catamaran suffered a stock decline. Johnson & Johnson is potentially reshaping its business, and Intermune is a potential takeover target. Questcore Pharmaceuticals faces controversy and uncertainties.

Key Insights

• 🧘 Anaka's FDA approval and partnership with Johnson & Johnson position it for market success.
• 💪 Miland Pharmaceuticals' strong financial results and potential M&A activity demonstrate its growth prospects.
• ❓ Catamaran's stock decline highlights the importance of meeting earnings expectations.
• 👨‍💼 Johnson & Johnson's potential reshaping of its business reflects the impact of patent expiration.
• 🎯 Intermune's successful clinical trial and unique drug make it an attractive takeover target.
• 🤨 The controversies surrounding Questcore Pharmaceuticals raise significant doubts about its future prospects.
• ✳️ Investors should closely monitor the healthcare market for potential opportunities and risks.

Transcript

hi fools I'm David Williamson and welcome to Market checkup the mle Fool's Healthcare focused investing show we're going to go over some of the week's winners and losers we have a nice big Pharma headline for you a fun game over who could buy an upand cominging biotech and also a stock with a lot of controversy around it that I will be watching clo... Read More

Questions & Answers

Q: What is the significance of FDA approval for Anaka's osteoarthritis treatment?

FDA approval validates the effectiveness and safety of the treatment, giving Anaka a competitive advantage in the market. Partnering with Johnson & Johnson also provides strong support for marketing and distribution.

Q: Why did Catamaran experience a stock decline despite strong financial results?

The decline was primarily due to lower than expected earnings per share guidance for 2014. The market had priced the stock higher, leading to a selloff when the guidance fell short of expectations.

Q: Why is Intermune considered a potential takeover target?

Intermune's first-in-class idiopathic pulmonary fibrosis (IPF) drug has shown promising results in clinical trials. Its success and potential market potential make it an attractive acquisition target for pharmaceutical companies.

Q: What are the controversies surrounding Questcore Pharmaceuticals?

There have been allegations of questionable business practices and misleading marketing of its flagship product, Acthar. The recent report by Citrone Research, claiming low levels of active ingredient in Acthar, has added to the uncertainties surrounding the company.

Summary & Key Takeaways

• Anaka has received FDA approval for its osteoarthritis treatment and will be marketed by Johnson & Johnson.

• Miland Pharmaceuticals impressed with strong quarterly results and potential M&A activity.

• Catamaran experienced stock decline due to lower than expected earnings guidance.

• Johnson & Johnson is rumored to be selling its low-margin diagnostic business.

• Intermune's stock experienced significant growth after successful clinical trials, making it a potential takeover target.

• Questcore Pharmaceuticals faces controversy and allegations of questionable business practices.